Clinical Collaboration

Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 486 (CSE: PILL) (OTCQB: CTABF) (NASDAQ: NEPT) (TSX: NEPT) (CSE: BEV) (OTCQB: BVNNF) | 10/27/2020

… has launched Australia’s largest observational study ever undertaken for medical cannabis. Canntab, through the products it supplies to CANN Global Ltd., which is a direct participant in the study, will be participating in this clinical collaboration with major Australian clinics and hospitals to complete the Cannabinoid Medicine Observational Study (“CMOS”) that will collect data from 20,000 patients nationwide over 5 years. CMOS aims to assess the safety and efficacy of …

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark | 10/26/2020

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark October 26, 2020 0 October 26, 2020 Philips Clinical Collaboration Platform supports telehealth and other connectivity initiatives to increase collaboration across hospitals Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a regional informatics project that consolidates radiology and nuclear medicine imaging data. The …

Follow Clinical Collaboration:    

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark | 10/26/2020

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark Posted by admin on in PRESS RELEASES 0 Views October 26, 2020 Philips Clinical Collaboration Platform supports telehealth and other connectivity initiatives to increase collaboration across hospitals Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a regional informatics project that consolidates radiology and …

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark | 10/26/2020

October 26, 2020 Philips Clinical Collaboration Platform supports telehealth and other connectivity initiatives to increase collaboration across hospitals Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a regional informatics project that consolidates radiology and nuclear medicine imaging data. The Region of Southern Denmark now has a single system for storing, retrieving, and viewing clinical images across all the …

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark | 10/26/2020

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark October 26, 2020 Posted in Press Releases October 26, 2020 Philips Clinical Collaboration Platform supports telehealth and other connectivity initiatives to increase collaboration across hospitals Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a regional informatics project that consolidates radiology and nuclear medicine …

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark | 10/26/2020

October 26, 2020 PRESS RELEASES October 26, 2020 Philips Clinical Collaboration Platform supports telehealth and other connectivity initiatives to increase collaboration across hospitals Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a regional informatics project that consolidates radiology and nuclear medicine imaging data. The Region of Southern Denmark now has a single system for storing, retrieving, and viewing …

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark | 10/26/2020

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark Closed by admin October 26, 2020 Press Releases October 26, 2020 Philips Clinical Collaboration Platform supports telehealth and other connectivity initiatives to increase collaboration across hospitals Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a regional informatics project that consolidates radiology and nuclear …

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark | 10/26/2020

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark October 26, 2020 Philips Clinical Collaboration Platform supports telehealth and other connectivity initiatives to increase collaboration across hospitals Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a regional …

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark | 10/26/2020

October 26, 2020 Asean , PRESS RELEASES October 26, 2020 Philips Clinical Collaboration Platform supports telehealth and other connectivity initiatives to increase collaboration across hospitals Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a regional informatics project that consolidates radiology and nuclear medicine imaging data. The Region of Southern Denmark now has a single system for storing, retrieving, and …

ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital | PR Newswire | 9/23/2020

… be exclusively funded by Shanghai Healthcare Capital (“SHC”), managed by SIIC Capital, where Shanghai Pharma is one of the founding strategic cornerstone LPs. ImmVira Logo In August 2020 , ImmVira and Shanghai Pharma announced a clinical collaboration and exclusive license agreement for ImmVira’s MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors. “We warmly welcome SHC to be our strategic investor,” said Grace …

ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital | 9/23/2020

… financing will be exclusively funded by Shanghai Healthcare Capital (“SHC”), managed by SIIC Capital, where Shanghai Pharma is one of the founding strategic cornerstone LPs. In August 2020 , ImmVira and Shanghai Pharma announced a clinical collaboration and exclusive license agreement for ImmVira’s MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors. “We warmly welcome SHC to be our strategic investor,” said Grace …

ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital | 9/23/2020

ImmVira Group reports this round of financing will be exclusively funded by Shanghai Healthcare Capital (“SHC”), managed by SIIC Capital, where Shanghai Pharma is one of the founding strategic cornerstone LPs. In August 2020 , ImmVira and Shanghai Pharma announced a clinical collaboration and exclusive license agreement for ImmVira’s MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors. “We warmly welcome SHC to …

ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital | BioSpace | 9/23/2020

… financing will be exclusively funded by Shanghai Healthcare Capital (“SHC”), managed by SIIC Capital, where Shanghai Pharma is one of the founding strategic cornerstone LPs. In August 2020 , ImmVira and Shanghai Pharma announced a clinical collaboration and exclusive license agreement for ImmVira’s MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors. “We warmly welcome SHC to be our strategic investor,” said Grace …

Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit | Business Wire | 9/22/2020

… allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta ® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration . For more information, visit www.humanigen.com . Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that …

Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit | Business Wire | 9/22/2020

… allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta ® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration . For more information, visit www.humanigen.com . Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that …

Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen’s COVID-19 Therapeutic Candidate Lenzilumab | Business Wire | 9/15/2020

… allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta ® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration . For more information, visit www.humanigen.com . Forward-looking statements of Humanigen This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management …

Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1 | PR Newswire | 9/15/2020

… ray energies capability. This new capability not only enhances visibility of soft tissue, but also provides more accurate information about tissue density allowing dosimetrists to plan more precisely. This feature was validated through a clinical collaboration with the Roberts Proton Therapy Center at the University of Pennsylvania 1 . Also included in Eclipse v16.1 is the first clinical release of GPU Monte Carlo proton dose calculation technology, that was evaluated in …

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma | Benzinga | 9/14/2020

STAMFORD, Conn., Sept. 14, 2020 (GLOBE NEWSWIRE) – SpringWorks Therapeutics, Inc. (NASDAQ: SWTX ), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical collaboration and supply agreement with Janssen Biotech, Inc. (Janssen) to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with Janssen’s bispecific antibody targeting B-cell maturation …

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma | Globe Newswire | 9/14/2020

… NEWSWIRE) – SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical collaboration and supply agreement with Janssen Biotech, Inc. (Janssen) to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with Janssen’s bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, teclistamab, in …

Humanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring Board | Business Wire | 9/14/2020

… allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta ® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration . For more information, visit www.humanigen.com . Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that …

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma | BioSpace | 9/14/2020

… NEWSWIRE) – SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical collaboration and supply agreement with Janssen Biotech, Inc. (Janssen) to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with Janssen’s bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, teclistamab, in …

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma - GuruFocus.com | 9/14/2020

… GLOBE NEWSWIRE) – SpringWorks Therapeutics, Inc. ( SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical collaboration and supply agreement with Janssen Biotech, Inc. (Janssen) to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with Janssen’s bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, teclistamab, in …

NEHII Selects Collective Medical to Support Multi-State ADT Alerting for Care Collaboration | Business Wire | 9/11/2020

… the country,” says Chris Klomp, CEO of Collective Medical. “We are honored to be a part of this initiative and serve NEHII partners throughout the Midwest to demonstrate what can be achieved by enabling clinical collaboration .” Learn more about the benefits of becoming a NEHII partner by visiting www.nehii.org or via email at [email protected] . About NEHII: NEHII’s mission is to bring trust and value to health information technology by …

Genomind Announces Major Industry-Leading HLA-A Test Innovation on its Comprehensive Mental Health Pharmacogenetics (PGx) Test, Increasing Utility for Tens of Thousands of Clinicians and Patients | Business Wire | 9/10/2020

… mental health company singularly focused on filling the innovation gap in mental health care through novel, genetics-based tools. Supported by a world-class genetics lab, a unique heritage of clinical mental health expertise, clinical collaboration and consultation, state-of-the-art digital tools and telemental health enabling services, Genomind is empowering a new standard of care. Its flagship product, Genomind Professional PGx Express, is the most comprehensive pharmacogenetic testing …

Intensity Therapeutics Doses First Patients with Combination of INT230-6 and Merck’s Keytruda® in Phase 2 Studies | Business Wire | 9/9/2020

… only attacks the injected tumor, but also non-injected tumors. The Company executed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Vaccine Branch in 2014. The Company has a clinical collaboration with Merck Sharpe & Dohme (Merck) to evaluate the combination of INT230-6, Intensity’s lead product candidate, and KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy, in patients with advanced solid malignancies. The …

Biotech

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma | Globe Newswire | 9/14/2020

Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities September 14, 2020 06:30 ET Source: SpringWorks Therapeutics, Inc. STAMFORD, Conn., Sept. 14, 2020 (GLOBE NEWSWIRE) – SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical collaboration and supply agreement with Janssen Biotech, Inc …

Medicare

NEHII Selects Collective Medical to Support Multi-State ADT Alerting for Care Collaboration | Business Wire | 9/11/2020

… compliant with the admissions, discharge and transfer (ADT) notifications Conditions of Participation (CoP) included as part of the Centers for Medicare and Medicaid Services (CMS) Interoperability and Patient Access Rule . The new CoP, which takes … the Midwest to demonstrate what can be achieved by enabling clinical collaboration.” Learn more about the benefits of becoming a NEHII partner by visiting www.nehii.org or via email at [email protected] . About NEHII: NEHII’s mission …

Food and Drug Administration

NANOBIOTIX Announces Half-year Financial Statements as at June 30, 2020 | Business Wire | 9/4/2020

… the Company’s statutory auditors. Major milestones achieved during the half-year include: Granted Fast Track designation by the United States Food and Drug Administration (US FDA) for the treatment of the patients with locally advanced … product and its use in a phase III clinical trial. Clinical Collaboration Updates In May 2020, Nanobiotix announced that the first trial from its clinical collaboration with the University of Texas MD Anderson Cancer Center …

COVID-19

Humanigen Appoints Edward P. Jordan as Chief Commercial Officer | Business Wire | 8/24/2020

… Southern New Hampshire University. “We have been actively planning for launch as we develop our lead drug candidate, lenzilumab, for COVID-19. Ed’s long tenure in senior commercial leadership roles, coupled with his track record … with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com . Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment …

National Cancer Institute

Humanigen Appoints Senior Executives to Management Team | Business Wire | 7/7/2020

… MD, MBA, Chief Executive Officer, Humanigen. Dr. Chappell began his career as a Howard Hughes Medical Institute fellow at the National Cancer Institute where he studied tumor immunology and published in the field of T … with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment …

Home Health

HHCN Poll: 24% of Home Health Agencies Have Laid Off Therapy Staff Post-PDGM | Home Health Care News | 4/14/2020

… appear to be a substantial drop in overall therapy utilization, according to the survey. About one-third of the surveyed home health professionals said their organization’s therapy utilization has decreased by at least 15% since … avoiding therapy services entirely, Bayada has aimed to foster more clinical collaboration, giving PTs, OTs and SLPs more chances to work alongside nurses in “clinical huddles.” The goal of the huddles: to make sure each …

Clinical Research

Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma | PR Newswire | 1/13/2020

… reference their respective Investigational New Drug applications and will work collaboratively to obtain necessary regulatory and institutional approvals. In this clinical collaboration, Actinium will provide drug product, support for its administration and certain trial costs … for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation …

Patient Engagement

QliqSOFT Announces Healthcare Chatbot that Solves Patient Engagement, Instantly. | Business Wire | 1/9/2020

… intents and dialogue flows or customize Quincy to build chatbots to suit your unique needs. (Graphic: Business Wire) Qliqsoft’s conversational patient engagement platform provides patients care-related information via mobile texting and web-based messaging … architecture, QliqSOFT’s Secure Texting, On-Call Scheduling, Patient Communication, and Clinical Collaboration solutions are trusted by over 1,000 Hospitals, Home Health, and Hospice Organizations to deliver HIPAA-compliant, reliable, and real-time communication between doctors …

Feinberg School of Medicine

Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer | Globe Newswire | 1/9/2020

… Institute, University of Colorado and University of Vermont, where he headed Human Medical Genetics. He is an alumnus of the Feinberg School of Medicine at Northwestern University, the Institute of Materials Research and Innovation, University … small cell lung cancer (NSCLC). Kitov has entered into a clinical collaboration agreement with Bristol Myers Squibb (NYSE: BMY ) for the planned Phase 1/2 clinical trials to evaluate the combination of CM-24 with the …

American Society of Clinical Oncology

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

CAR-T

Humanigen Terminates Exploration of Potential Rights Offering - GuruFocus.com | 12/2/2019

… December 2, 2019 / Humanigen, Inc., ( OTCQB: HGEN ) (“Humanigen”), a clinical stage biopharmaceutical company focused on the development of next generation CAR-T and other cell therapies, announced today that it is has terminated the process … GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the sequential use of lenzilumab with Yescarta ® , axicabtagene ciloleucel, in a multicenter clinical …

Electronic Medical Record

Hyland Healthcare Launches New Products and Updates at RSNA 2019 | PR Newswire | 12/1/2019

… 4300 in the South Hall. Each pavilion showcases solutions that address critical challenges in imaging and healthcare, including workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care … link it to core clinical and business applications such as electronic medical records (EMR) and enterprise resource planning (ERP) systems. Hyland Healthcare is the only technology partner that offers a full suite of content services …

EMR

Hyland Healthcare Launches New Products and Updates at RSNA 2019 | PR Newswire | 12/1/2019

… 4300 in the South Hall. Each pavilion showcases solutions that address critical challenges in imaging and healthcare, including workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care … core clinical and business applications such as electronic medical records (EMR) and enterprise resource planning (ERP) systems. Hyland Healthcare is the only technology partner that offers a full suite of content services and enterprise imaging …

PACS

Hyland Healthcare Launches New Products and Updates at RSNA 2019 | PR Newswire | 12/1/2019

… medical images across the entire enterprise while enhancing the radiologist’s expanded role in value-driven care. Significant product enhancements include: PACSgear Video Touch 4K , a new addition to Hyland Healthcare’s PACSgear MDR-Video Touch family … address critical challenges in imaging and healthcare, including workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care image integration. Chris Magyar , senior manager of product management for …

Enterprise Imaging

Hyland Healthcare Launches New Products and Updates at RSNA 2019 | PR Newswire | 12/1/2019

CHICAGO , Dec. 1, Hyland Healthcare , a leading global provider of content services and enterprise imaging, is unveiling a host of new products and updates at the Radiological Society of North America (RSNA) annual meeting in … address critical challenges in imaging and healthcare, including workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care image integration. Chris Magyar , senior manager of product management for …

Medical Imaging

Hyland Healthcare Shares Imaging Trends Ahead of RSNA 2019 | PR Newswire | 11/26/2019

… of imaging strategies . Hyland Healthcare’s cloud-neutral stance provides customers with configurable options for hosting some or all of their medical imaging in the cloud, which can alleviate the growing costs of on premise solutions … in the South Hall, features seven pavilions covering workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care image integration. For more information, visit HylandHealthcare.com and booth 4300 …

Medical Education

Global $1.66Bn Cognitive Collaboration Market Outlook to 2024 | PR Newswire | 11/26/2019

Clinical Collaboration and Medical Education Driving the Adoption of Cognitive Collaboration Solutions in the Healthcare Vertical 10.7 Retail 10.7.1 Growing Need to Offer Custom-Based Services to Customers Driving the Adoption of Cognitive Collaboration Solutions in the Retail Vertical 10.8 Others 11 Cognitive Collaboration Market By Region 11.1 Introduction 11.2 North America 11.2.1 United States 11.2.1.1 Rapid Growth of Technologies and Infrastructures to Boost the Adoption of AI-Based Collaboration …

Genomics

Cofactor Genomics Expands Leadership Team and Opens New Boston Predictive Immune Modeling CenterCofactor Genomics Expands Leadership Team and Opens New Boston Predictive Immune Modeling Center | 11/26/2019

Cofactor Genomics Expands Leadership Team and Opens New Boston Predictive Immune Modeling Center Boston, MA – September 26, 2019 – Today Cofactor Genomics announced that it has expanded the leadership team with the promotion of Natalie LaFranzo, PhD to Vice President of Market Development. Dr. LaFranzo’s amplified leadership role includes clinical collaboration management, corporate partnerships, and strategic marketing. Dr. LaFranzo has been with Cofactor most recently for three years, with previous roles …

Clinical Data

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress | The Wapakoneta Daily News | 11/22/2019

… Zymeworks and its collaborator BeiGene, Ltd. plan to advance ZW25 into potentially registration-enabling global studies in HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA), based on these durable and consistent clinical data. “The promising ZW25 data at ESMO Asia further build momentum for the expanding footprint of our ZW25 clinical development program with BeiGene,” said Ali Tehrani, Ph.D., President and CEO of Zymeworks. “Cancer is a global …

Diagnostic Imaging

Fujifilm Presents Comprehensive Enterprise Imaging Portfolio At RSNA 2019 | PR Newswire | 11/21/2019

… U.S.A. , Inc. “That calls for an enterprise imaging strategy that is capable of merging platforms, augmenting siloed systems, and empowering clinical collaboration; allowing providers to see the whole patient, so they can treat the whole … FUJIFILM Medical Systems U.S.A. , Inc. is a leading provider of diagnostic imaging products and medical informatics solutions that meet the evolving needs of healthcare facilities both today and tomorrow. From an unrivaled selection of digital …

Digital Health

ARTIDIS Joins the TMC Accelerator Device Cohort to Ensure That Its Cancer Diagnostic and Therapeutic Optimization Innovation Gains Early Access to the US Market | PR Newswire | 11/18/2019

… best place to take patient care to the next level. It also enables us to further strengthen ongoing scientific and clinical collaborations focusing on breast, lung and pancreatic cancer with our colleagues from three major … complex health care issues of today and cultivating cutting-edge digital health applications and medical devices. For more information, please visit www.tmc.edu . About ARTIDIS AG ARTIDIS AG is a spinoff from the Biozentrum, University of …

NIH

Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results | PR Newswire | 11/12/2019

clinical collaboration agreement (ClinicalTrials.gov Identifier: NCT03835533). DNA-encoded monoclonal antibodies (dMAb ® )/DNA-encoded Bi-specific T Cell Engagers (dBTE) Inovio and its collaborator, The Wistar Institute, received a $4.6 million grant from the National Institutes of Health (NIH) in support of innovative research of antimicrobial resistance (AMR) and continued development of Inovio’s DNA-encoded monoclonal antibodies (dMAb ® ) platform. Using direct local delivery into the body by the CELLECTRA ® platform, the …

HIPAA

Caregility Helps Philips, Department of Veterans Affairs, Veterans of Foreign Wars and The American Legion Bring Local Telehealth Services to Rural Veterans | PR Newswire | 11/11/2019

EATONTOWN, N.J. Caregility , a clinical collaboration and communications company changing the point of care, today announced the company’s involvement in the ATLAS pilot project, an initiative to bring virtual care offerings from the Department of … technology and equipment donated by Philips and Caregility combined with HIPAA-trained attendants provided by CareLink, the pods improve access to care for veterans in underserved areas where there are limited healthcare providers. “Telehealth is …

Virtual Care

Caregility Helps Philips, Department of Veterans Affairs, Veterans of Foreign Wars and The American Legion Bring Local Telehealth Services to Rural Veterans | PR Newswire | 11/11/2019

EATONTOWN, N.J. Caregility , a clinical collaboration and communications company changing the point of care, today announced the company’s involvement in the ATLAS pilot project, an initiative to bring virtual care offerings from the Department of Veterans Affairs (VA) to veterans in targeted rural areas. Caregility-Project-Atlas-Ribbon-Cutting ATLAS, which stands for Accessing Telehealth through Local Area Stations, is a collaboration between the VA, Veterans of Foreign Wars (VFW …

Telehealth

Caregility Helps Philips, Department of Veterans Affairs, Veterans of Foreign Wars and The American Legion Bring Local Telehealth Services to Rural Veterans | PR Newswire | 11/11/2019

EATONTOWN, N.J. Caregility , a clinical collaboration and communications company changing the point of care, today announced the company’s involvement in the ATLAS pilot project, an initiative to bring virtual care offerings from the Department of Veterans Affairs (VA) to veterans in targeted rural areas. Caregility-Project-Atlas-Ribbon-Cutting ATLAS, which stands for Accessing Telehealth through Local Area Stations, is a collaboration between the VA, Veterans of Foreign Wars (VFW …

Pfizer

ReCode Therapeutics Strengthens Leadership Team With New Appointments | Business Wire | 9/9/2020

… clinical collaborations, IP licensing, commercial distribution and manufacturing agreements. Prior to joining ReCode, Mr. Agarwal was vice president of corporate development at Forty Seven, Inc. (acquired by Gilead). Before Forty Seven, he held the roles of vice president, business development at Revance, and as senior director, corporate development and strategy at Anacor (acquired by Pfizer), and director, global BD&L at Forest Pharmaceuticals (acquired by Allergan, now AbbVie). He received …

AbbVie

ReCode Therapeutics Strengthens Leadership Team With New Appointments | Business Wire | 9/9/2020

… clinical collaborations, IP licensing, commercial distribution and manufacturing agreements. Prior to joining ReCode, Mr. Agarwal was vice president of corporate development at Forty Seven, Inc. (acquired by Gilead). Before Forty Seven, he held the roles of vice president, business development at Revance, and as senior director, corporate development and strategy at Anacor (acquired by Pfizer), and director, global BD&L at Forest Pharmaceuticals (acquired by Allergan, now AbbVie). He received …

Gilead

ReCode Therapeutics Strengthens Leadership Team With New Appointments | Business Wire | 9/9/2020

… clinical collaborations, IP licensing, commercial distribution and manufacturing agreements. Prior to joining ReCode, Mr. Agarwal was vice president of corporate development at Forty Seven, Inc. (acquired by Gilead). Before Forty Seven, he held the roles of vice president, business development at Revance, and as senior director, corporate development and strategy at Anacor (acquired by Pfizer), and director, global BD&L at Forest Pharmaceuticals (acquired by Allergan, now AbbVie). He received …

Merck

Humanigen Appoints Edward P. Jordan as Chief Commercial Officer | Business Wire | 8/24/2020

… roles at AMAG Pharmaceuticals and Teva Pharmaceuticals. Mr. Jordan began his career at Schering-Plough, prior to the acquisition by Merck, and spent 18 years in sales and marketing leadership positions. Mr. Jordan received dual … with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com . Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment …

Merck & Co

QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma | PR Newswire | 8/13/2020

… 12, 2020 /PRNewswire/ – QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals, is pleased to announce that it has entered into an agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ , USA), to evaluate use of its lead molecule tigilanol tiglate, in combination with Keytruda® (pembrolizumab) in patients with unresectable melanoma. Dr Victoria Gordon , Managing Director and CEO of QBiotics, said, “We are …

Eli Lilly

Zentalis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Update | Globe Newswire | 8/13/2020

… 20.0 million Series A financing to establish Zentera Therapeutics, a majority-owned Chinese joint venture Entered into strategic collaborations with Eli Lilly and Tavros Therapeutics to further advance oncology pipeline NEW YORK and SAN DIEGO … Program Highlights: In July 2020, the Company entered into a clinical collaboration with Eli Lilly and Company to evaluate the combination of ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, and …

Immunomedics

Immunomedics Extends Deal With Roche for Two New Studies - July 14, 2020 - Zacks.com | 7/14/2020

Immunomedics Inc. ( IMMU - Free Report ) announced that it will extend its clinical collaboration with Roche ( RHHBY - Free Report ) with two new studies evaluating the combination of anti-Trop-2 antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) of the former and the latter’s Tecentriq (atezolizumab) in patients with metastatic urothelial cancer (mUC) and metastatic non-small cell lung cancer (mNSCLC). Tecentriq is Roche’s programmed cell death ligand 1 (PD-L1 …

Bristol-Myers

Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody | Globe Newswire | 7/8/2020

clinical collaboration agreement with Bristol-Myers Squibb (BMS) Company, and is expected to begin in the second half of 2020. “We are very pleased with this new addition to our patent coverage in the EU, which, together with the corresponding US patent which has been granted earlier this year, strongly positions CM24 as a unique approach for treating cancer patients. We look forward to the anticipated initiation of our planned …

Bristol-Myers Squibb

Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody | Globe Newswire | 7/8/2020

clinical collaboration agreement with Bristol-Myers Squibb (BMS) Company, and is expected to begin in the second half of 2020. “We are very pleased with this new addition to our patent coverage in the EU, which, together with the corresponding US patent which has been granted earlier this year, strongly positions CM24 as a unique approach for treating cancer patients. We look forward to the anticipated initiation of our planned …

Novartis

Humanigen Appoints Senior Executives to Management Team | Business Wire | 7/7/2020

… Emerging Markets, covering 42 countries in the Middle East, West Asia and Africa Region. He also held leadership positons at Novartis and at Roche Pharmaceuticals. “We are pleased that both Dr. Chappell and Mr. Tousley … with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com Forward-Looking Statements This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment …

Genentech

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer | Business Wire | 7/2/2020

PARIS- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase … in its territory. Tecentriq ® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. About CONTACT-01 CONTACT-01 is a global, multicenter, randomized, Phase III, open-label study that aims to …

Encompass Health

HHCN Poll: 24% of Home Health Agencies Have Laid Off Therapy Staff Post-PDGM | Home Health Care News | 4/14/2020

… avoided knee-jerk therapy reactions because of PDGM. Instead of avoiding therapy services entirely, Bayada has aimed to foster more clinical collaboration, giving PTs, OTs and SLPs more chances to work alongside nurses in “clinical … our visit approach. Any of that,” April Anthony, CEO of Encompass Health’s (NYSE: EHC) home health and hospice segment, previously told HHCN . “We really feel like the whole therapy-behavior change is over-cooked.” While …

Caregility

Caregility Announces New Features in HIPAA Compliant iConsult Mobile App to help in fight against COVID-19 | PR Newswire | 4/1/2020

EATONTOWN, N.J. Caregility , a clinical collaboration and communications company focused on providing secure, reliable two-way audio and video communications for any device and clinical workflow, in both inpatient and outpatient settings, announces it has developed new features to address the challenges of using iPads and Smart Tablets with remote monitoring solutions in patient rooms. The new features enable secure remote calling into the room without the need for a …

GlaxoSmithKline

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 | Globe Newswire | 3/18/2020

… clinical collaborations to evaluate nirogacestat in combination with GlaxoSmithKline’s BCMA antibody-drug conjugate belantamab mafodotin and with Allogene’s allogeneic BCMA CAR-T cell therapy ALLO-715. About Nirogacestat Nirogacestat is an investigational, oral, selective, small molecule gamma-secretase inhibitor in Phase 3 clinical development for desmoid tumors, which are rare and often debilitating and disfiguring soft-tissue tumors. Gamma secretase cleaves multiple transmembrane protein complexes, including Notch, which is believed …

Biogen

Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer | Globe Newswire | 1/9/2020

… our team. Furthermore, Dr. Liang’s prior leadership experience across all phases of clinical development at leading large biopharmaceutical companies, including Biogen, IDEC and Amgen, will be invaluable to Kitov’s clinical development plans.” Dr. Liang previously … small cell lung cancer (NSCLC). Kitov has entered into a clinical collaboration agreement with Bristol Myers Squibb (NYSE: BMY ) for the planned Phase 1/2 clinical trials to evaluate the combination of CM-24 with the …

Medtronic

ViewRay Announces Collaborations with Elekta and Medtronic | BioSpace | 12/3/2019

Medtronic (NYSE: MDT) to enter into a clinical collaboration in an area of mutual interest that includes exploring the clinical benefits of the MRIdian MR-guided radiation therapy system. In connection with the collaboration, Medtronic has committed to invest in a minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement. ViewRay’s largest shareholder, Fosun International Limited (“Fosun”), has also committed capital up to …

MRIdian

ViewRay Announces Collaborations with Elekta and Medtronic | BioSpace | 12/3/2019

clinical collaboration in an area of mutual interest that includes exploring the clinical benefits of the MRIdian MR-guided radiation therapy system. In connection with the collaboration, Medtronic has committed to invest in a minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement. ViewRay’s largest shareholder, Fosun International Limited (“Fosun”), has also committed capital up to an amount that would enable it to …

Seattle Genetics

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

Weather AP Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer 1 hr ago Save BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Dec 2, 2019– Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the …

Hyland Healthcare

Hyland Healthcare Launches New Products and Updates at RSNA 2019 | PR Newswire | 12/1/2019

CHICAGO , Dec. 1, Hyland Healthcare , a leading global provider of content services and enterprise imaging, is unveiling a host of new products and updates at the Radiological Society of North America (RSNA) annual meeting in … address critical challenges in imaging and healthcare, including workflow optimization, clinical collaboration, enterprise-first imaging, patient experience, connected care and content, and point-of-care image integration. Chris Magyar , senior manager of product management for …

BeiGene

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress | The Wapakoneta Daily News | 11/22/2019

… mini oral presentation by Dr. Do-Youn Oh, study investigator and Professor at Seoul National University, at the ESMO Asia 2019 Congress, taking place November 22 - 24 in Singapore. Zymeworks and its collaborator BeiGene, Ltd. plan to advance ZW25 into potentially registration-enabling global studies in HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA), based on these durable and consistent clinical data. “The promising ZW25 data at ESMO …

Compugen

EuroBiotech: More Articles of Note | FierceBiotech | 11/14/2019

Compugen posted initial phase 1 data on its anti-PVRIG antibody. The trial detected early signs of efficacy in microsatellite stable colorectal cancer. Statement Lytix Biopharma formed a clinical collaboration with Iovance Biotherapeutics . The companies will test Lytix’s oncolytic peptide in combination with Iovance’s T cell therapy. Release SUBSCRIBE NOW Poxel said FDA feedback supports its plan to use the 505(b)(2) pathway to file for approval in nonalcoholic …

Iovance Biotherapeutics

EuroBiotech: More Articles of Note | FierceBiotech | 11/14/2019

clinical collaboration with Iovance Biotherapeutics . The companies will test Lytix’s oncolytic peptide in combination with Iovance’s T cell therapy. Release SUBSCRIBE NOW Poxel said FDA feedback supports its plan to use the 505(b)(2) pathway to file for approval in nonalcoholic steatohepatitis. The French biotech plans to rely on Actos data in its filing. Statement Lunac Therapeutics spun out of the University of Leeds with £2.7 million ($3.5 million …

Regeneron Pharmaceuticals

Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results | PR Newswire | 11/12/2019

… and INO-9012, an immune activator encoding IL-12, in combination with Libtayo ® , a PD-1 blocking antibody produced by Regeneron Pharmaceuticals in collaboration with Sanofi. Key interim data from the 52-patient clinical trial … Cancer Research Institute (CRI), as part of Inovio’s previously established clinical collaboration agreement (ClinicalTrials.gov Identifier: NCT03835533). DNA-encoded monoclonal antibodies (dMAb ® )/DNA-encoded Bi-specific T Cell Engagers (dBTE) Inovio and its collaborator, The Wistar …

Clovis Oncology

Clovis Oncology (CLVS) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/8/2019

… 2019 , 8:30 a.m. ET Contents: Prepared Remarks: Operator Ladies and gentlemen, thank you for standing by, and welcome to the Clovis Oncology third-quarter 2019 earnings conference call. [Operator instructions] I would now like to … compound FAP-2286. We remain very enthusiastic about our ongoing clinical collaboration with Bristol-Myers Squibb, and I’ll take a moment to review our combination studies for both Rubraca and lucitanib with nivolumab. I’ll begin …

Nektar Therapeutics

Nektar Therapeutics (NKTR) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/7/2019

… 2019 , 5:00 p.m. ET Contents: Prepared Remarks: Operator Ladies and gentlemen, thank you for standing by. And welcome to the Nektar Therapeutics Third Quarter 2019 Financial Results Conference Call. [Operator Instructions] After the speakers presentation … utilize the ADCC Mechanism. As you know we had a preclinical collaboration in place with Janssen for NKTR-255 and they are currently evaluating the agent in combination with several different therapies in their oncology …

William Blair

Aileron Therapeutics, Inc. (ALRN) CEO Manuel Aivado on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/10/2019

… Aivado - President & Chief Executive Officer Vojislav Vukovic - Chief Medical Officer Allen Annis - Head of Research Conference Call Participants Rob Andrew - William Blair Justin Zelin - Canaccord Jacques Villefranc - LifeSci Capital Operator Ladies and gentlemen, thank you … move forward in liposarcoma, I know you mentioned there’s a clinical collaboration there with Pfizer. Are there any plans for kind of partnership in that program particularly given that combination with Ibrance? Thanks very much …

Agenus Inc. (AGEN) CEO Dr. Garo Armen on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/4/2019

… CEO Anna Wijatyk - Head, Clinical Development and Operations Christine Klaskin - VP, Finance Conference Call Participants Biren Amin - Jefferies Matt Phipps - William Blair Harshita Polishetty - B. Riley FBR Inc. Operator Good day, ladies and gentlemen. And … development as well as for some of the collaborative – in clinical collaborations that we’re contemplating. And so, what you will see is that the accrual will be open. And to our discretion, we’ve completed our …

Merrill Lynch

Clovis Oncology (CLVS) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/8/2019

… for both Rubraca and lucitanib, and then discuss our newest compound FAP-2286. We remain very enthusiastic about our ongoing clinical collaboration with Bristol-Myers Squibb, and I’ll take a moment to review our combination … of America. Please go ahead. Tazeen Ahmad – Bank of America Merrill Lynch – Analyst Hi, good morning. Thanks for taking my questions. Pat, just your view about the European market. We’ve talked now for a while …

Gilead Sciences, Inc. (GILD) CEO Daniel O’Day on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/3/2019

… Brian Abrahams - RBC Capital Markets Geoffrey Porges - SVB Leerink Michael Yee - Jeffries Carter Gould - UBS Ying Huang - Bank of America Merrill Lynch Umer Raffat - Evercore Phil Nadeau - Cowen and Company Cory Kasimov - JPMorgan Ronny Gal … few weeks ago we announced our intent to enter into clinical collaboration with Novo Nordisk to evaluate the utility of combining their approved GLP-1 drug semaglutide with both our FXR agonists cilofexor and our …

RBC Capital Markets

Encompass Health Corporation (EHC) CEO Mark Tarr on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 4/26/2019

… Home Health and Hospice Conference Call Participants Matt Larew - William Blair Brian Tanquilut - Jefferies AJ Rice - Credit Suisse Frank Morgan - RBC Capital Markets Joanna Gajuk - Bank of America Dana Hanley - Stephens Kevin Ellich - Craig Hallum … this transaction in June. We continue to make progress on clinical collaborations and achieved a 36% clinical collaboration rate in the first quarter of 2019, a 250 basis point increase over the first quarter of …

Incyte (INCY) Q3 2017 Results - Earnings Call Transcript | Seeking Alpha | 10/31/2017

… Eric Schmidt - Cowen & Co. LLC Salveen Richter - Goldman Sachs & Co. LLC Ying Huang - Bank of America Merrill Lynch Brian Abrahams - RBC Capital Markets LLC Alethia Young - Credit Suisse Securities (NYSE: USA ) LLC M. Ian Somaiya … that we have agreed with AstraZeneca to expand our existing clinical collaboration and move into Phase 3 development in a trial which will study epacadostat plus durvalumab in patients with non-small cell lung cancer …

Mayo Clinic

Lenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings Journal | Business Wire | 9/1/2020

… The manuscript , titled “GM-CSF neutralization with lenzilumab in severe COVID-19 patients: A case-control study” was published in Mayo Clinic Proceedings, a premier peer-reviewed journal. “We believe these to be some of … with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com release contains . Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events …

University of Texas MD Anderson Cancer Center

Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020 | Business Wire | 7/17/2020

clinical collaboration with The University of Texas MD Anderson Cancer Center has been allowed to proceed by the US Food and Drug Administration (FDA). At ASCO 2020, Nanobiotix announced positive new data from the expansion part of its phase I trial, evaluating the potential of first-in-class NBTXR3 activated by radiation therapy to improve treatment outcomes for elderly patients with locally advanced head and neck cancer ineligible for chemotherapy …

MD Anderson Cancer Center

Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020 | Business Wire | 7/17/2020

clinical collaboration with The University of Texas MD Anderson Cancer Center has been allowed to proceed by the US Food and Drug Administration (FDA). At ASCO 2020, Nanobiotix announced positive new data from the expansion part of its phase I trial, evaluating the potential of first-in-class NBTXR3 activated by radiation therapy to improve treatment outcomes for elderly patients with locally advanced head and neck cancer ineligible for chemotherapy …

The University of Texas MD Anderson Cancer Center

CarThera and KIYATEC Collaborate in Effort to Bring Personalized Medicine to Patients Stricken by Brain Cancer | Business Wire | 11/18/2019

… GREENVILLE, S.C. & PARIS–(BUSINESS WIRE)–Nov 18, 2019– KIYATEC, Inc. and CarThera announce today that they have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with … experts, John de Groot, M.D., professor and chairman ad interim, The University of Texas MD Anderson Cancer Center, who recognized the synergistic nature of their respective clinical initiatives. CarThera is currently conducting a multi-center …

Memorial Sloan Kettering Cancer Center

Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast Cancer | Business Wire | 10/7/2019

… Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing treatments for hormone driven cancers, today announced a Phase 2 clinical collaboration with the Wisconsin Oncology Network. This clinical collaboration will evaluate whether the addition … SOLTI and a first line (1L) biochemical recurrence study at Memorial Sloan Kettering Cancer Center, will provide clinicians with a complete picture of how Apristor works in advanced ER+,PR+,HER2- breast cancer and inform …

Harvard Medical School

Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel | Globe Newswire | 7/11/2019

… Therapeutics. In that role, she was responsible for all partnering activities, including most recently leading negotiations for their broad-based clinical collaborations with Bristol Meyers Squibb on NKTR-214. Dr. Decker also executed multiple additional … University School of Medicine and conducted her postdoctoral training at Harvard Medical School. General Counsel As General Counsel, Ms. Phillips will lead Atreca’s legal, compliance and intellectual property functions. She is a seasoned attorney with …

Massachusetts General Hospital

Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology | Benzinga | 5/20/2019

… treatment options for these patients. We hope this study will help us identify a new treatment paradigm.” Dr Brastianos is also an Assistant Physician in Medicine in the Department of Hematology/Oncology at Massachusetts General Hospital. Her research interests focus on metastatic brain cancer, and she has been extensively published in this field. Dr Brastianos will be joined on the study Steering Committee by distinguished expert clinicians from leading centres …

NYU Langone Health

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy | 11/29/2017

… focused on melanoma and cancers of the bladder, head and neck, and kidneys Emerging data supports expansion of collaboration with NYU Langone Health and its Perlmutter Cancer Center into melanoma and cancers of the bladder … the gut microbiota modulate immunotherapeutic responses. “Data from our ongoing clinical collaborations in melanoma show that gut bacteria signatures could help determine if a cancer immunotherapy will work,” said Bruce Roberts, Ph.D., Chief Scientific Officer …

Perlmutter Cancer Center

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy | 11/29/2017

… of the bladder, head and neck, and kidneys Emerging data supports expansion of collaboration with NYU Langone Health and its Perlmutter Cancer Center into melanoma and cancers of the bladder and lung Biosciences , an affiliate … the gut microbiota modulate immunotherapeutic responses. “Data from our ongoing clinical collaborations in melanoma show that gut bacteria signatures could help determine if a cancer immunotherapy will work,” said Bruce Roberts, Ph.D., Chief Scientific Officer …

Mount Sinai Health System

Bronx-Lebanon Hospital Center and Fit4D Secure Robin Hood Foundation Grant to Offer Diabetes Management Program | PRWeb | 11/28/2017

clinical collaboration with the Mount Sinai Health System, as well as 15 accredited residency and fellowship programs, are further indicators of its medical excellence. About Fit4D Fit4D’s mission is to improve the lives of people living with diabetes. Fit4D delivers effective patient programs through an optimized mix of humans and technology to deliver measurable outcomes in an affordable manner. The Fit4D clinical team of Certified Diabetes Educators (CDEs) is comprised …

Brooklyn Hospital Center, Brooklyn NY

The Brooklyn Hospital Center and Mount Sinai Heart Collaborate to Provide Comprehensive Cardiac Care in Downtown Brooklyn | PR Newswire | 11/20/2017

The Brooklyn Hospital Center and Mount Sinai Heart Collaborate to Provide Comprehensive Cardiac Care in Downtown Brooklyn Collaboration will ensure access to timely, convenient and lifesaving cardiac care News provided by 12:53 ET Share this article BROOKLYN, N.Y. , Nov. 20, 2017 /PRNewswire/ – The Brooklyn Hospital Center (TBHC) and Mount Sinai Heart hosted a breakfast reception on November 16 , to celebrate a clinical collaboration that provides access to comprehensive cardiac care …

Mount Sinai Hospital

The Brooklyn Hospital Center and Mount Sinai Heart Collaborate to Provide Comprehensive Cardiac Care in Downtown Brooklyn | PR Newswire | 11/20/2017

… PRNewswire/ – The Brooklyn Hospital Center (TBHC) and Mount Sinai Heart hosted a breakfast reception on November 16 , to celebrate a clinical collaboration that provides access to comprehensive cardiac care in Downtown Brooklyn . The alliance makes … Sharma, MD , Director of Clinical and Interventional Cardiology at The Mount Sinai Hospital. “ Mount Sinai has a 19-year track record of offering the highest level of patient safety in New York State , and we …

St Joseph Health

Agfa HealthCare Enterprise Imaging Platform Enters Southwestern Ontario Market | PR Newswire | 11/13/2017

… and the region, consolidating multiple imaging IT systems. “We are delighted these hospitals in the southwest region of Ontario have selected our Enterprise Imaging solutions. This will consolidate patient data and help facilitate clinical collaboration and continuity across the care continuum,” says Frank Pecaitis , senior vice president, North America , Sales and Marketing, Agfa HealthCare. The suite of Enterprise Imaging solutions includes the following applications: Enterprise Imaging for Radiology - a highly …

HealthSouth

HealthSouth Reports Results for Third Quarter 2017 and Updates Full-Year 2017 Guidance | CNBC | 10/27/2017

BIRMINGHAM, Ala., Oct. 26, 2017 /PRNewswire/ – HealthSouth Corporation (NYSE: HLS), one of the nation’s largest providers of post-acute healthcare services, offering both facility-based and home-based patient care, today reported its results of … associated with the Company’s rebranding and name change and TeamWorks clinical collaboration initiative. During the third quarter of 2017, the Company invested $1.5 million in its rebranding and name change and $2.3 million in its …

Aetna

(USA-VA-Chantilly) Clinical Collaboration Nurs | 5/15/2019

Aetna Clinical Collaboration Nurs in Chantilly , Virginia Req ID: 60138BR Full time telework position open to candidates in VA, WV, PA, OH. 10-25% travel is involved. The Provider Collaboration Clinician is responsible for a defined population in the assigned provider group(s). The clinician will use practice-wide data to identify clinical trends and opportunities for improvement and will partner with practice leadersh Job Function: Health Care Aetna is an …

(USA-WV-Charleston) Clinical Collaboration Nurs | 5/15/2019

Aetna Clinical Collaboration Nurs in Charleston , West Virginia Req ID: 60138BR Full time telework position open to candidates in VA, WV, PA, OH. 10-25% travel is involved. The Provider Collaboration Clinician is responsible for a defined population in the assigned provider group(s). The clinician will use practice-wide data to identify clinical trends and opportunities for improvement and will partner with practice leadersh Job Function: Health Care Aetna is …

Saqib Islam

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma | Globe Newswire | 9/14/2020

… life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical collaboration and supply agreement with Janssen Biotech, Inc. (Janssen) to evaluate SpringWorks Therapeutics’ investigational … with Janssen to study nirogacestat in combination with teclistamab,” said Saqib Islam, Chief Executive Officer of SpringWorks Therapeutics. “We now have three collaborations with industry-leading BCMA developers to evaluate nirogacestat in combinations across modalities …

John McHutchison

Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection | Globe Newswire | 8/27/2020

… Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assembly’s lead hepatitis B virus (HBV) core inhibitor candidate ABI … toward the ultimate goals of finite therapy and cure,” said John McHutchison, AO, MD, Chief Executive Officer and President of Assembly Biosciences. “One of our key priorities for this year has been to execute a …

Gisela Schwab

Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma | Yahoo News | 7/20/2020

CONTACT-03 is the third of three phase 3 pivotal trials that are part of a clinical collaboration with Roche – Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 … inhibitor-based regimens move to earlier lines of therapy,” said Gisela Schwab, M.D., President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis. “More data are needed to better understand the sequential use of …

Behzad Aghazadeh

Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers | Globe Newswire | 7/13/2020

… Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced an extension of its current clinical collaboration with Roche to evaluate Trodelvy, Immunomedics’ anti-Trop-2 ADC, in combination with … with Roche, a global leader in cancer therapy,” commented Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics. “We believe these combination studies will build a strong foundation for early-line cancer treatment developments.” Separately, Immunomedics also …

Ali Tehrani

Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities | BioSpace | 1/13/2020

… a chemotherapy-free treatment option to people with advanced HER2-positive, hormone receptor-positive breast cancer. Zymeworks entered into a clinical collaboration with Pfizer to advance the study. ZW25 achieved two additional regulatory milestones, recently … spectrum of HER2-expressing cancers and lines of therapy,” said Ali Tehrani, Ph.D., President and CEO at Zymeworks. “As our second therapeutic candidate, ZW49, continues to advance in the clinic, we are excited about its …

Kenji Yasukawa

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

Weather AP Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer 1 hr ago Save BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Dec 2, 2019– Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the …

Andrew Krivoshik

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through … with other agents in different stages of urothelial cancer,” said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head at Astellas. “We look forward to further evaluating enfortumab vedotin and pembrolizumab in …

Roger Dansey

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

… Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through … with previously untreated locally advanced or metastatic urothelial cancer,” said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. “Recent data from a phase 1b trial of enfortumab vedotin in combination with pembrolizumab showed evidence …

Howard W. Robin

Nektar Therapeutics (NKTR) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/7/2019

… Nektars website at nektar.com. With that, I will hand the call over to our President and CEO, Howard Robin, Howard? Howard W. Robin – President and CEO Thank you, Jennifer. Good afternoon everyone and thank you … utilize the ADCC Mechanism. As you know we had a preclinical collaboration in place with Janssen for NKTR-255 and they are currently evaluating the agent in combination with several different therapies in their oncology …

Jonathan Zalevsky

Nektar Therapeutics (NKTR) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/7/2019

… joining us today. With us are Howard Robin, our President and CEO; Gil Labrucherie our COO and CFO; and Dr. Jonathan Zalevsky our Head of R&D.On todays call, we expect to make forward-looking … utilize the ADCC Mechanism. As you know we had a preclinical collaboration in place with Janssen for NKTR-255 and they are currently evaluating the agent in combination with several different therapies in their oncology …

Tamar Howson

MEI Pharma Reports First Quarter Fiscal Year 2020 Results and Operational Highlights | PR Newswire | 11/7/2019

… primary focus remained on advancing the clinical development of ME-401, as well as voruciclib, while continuing to explore additional clinical collaborations and partnering opportunities to effectively leverage the potential of our drug candidates for … and 7.4 months (range 2.6-14.7 months), respectively. In July 2019 , Tamar Howson , M.S., MBA, a highly experienced business development executive with over 30 years of service in the pharmaceutical and biotechnology industry, joined the Board …

Charles M. Baum

Mirati Therapeutics Reports Third Quarter 2019 Fin | 11/5/2019

… 34 th Annual Meeting on November 9, 2019 . Announced on July 9, 2019 that the Company had entered into a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati’s investigational KRAS G12C … with Novartis, will significantly increase the eligible patient population,» said Charles M. Baum , M.D., Ph.D., President and Chief Executive Officer at Mirati. «We continue to expand and accelerate our KRAS programs and expect to continue …

Fred Hutchinson

Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230 | PR Newswire | 10/21/2019

DUBLIN , Oct. 21, Alkermes plc (Nasdaq: ALKS ) today announced that it has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center ( Fred Hutch ) for ALKS 4230, Alkermes’ immuno-oncology drug candidate. ALKS 4230 is a novel, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 (IL-2) receptor complex …

Fouad Namouni

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer | PR Newswire | 7/18/2019

… Myers Squibb Company (NYSE: BMY ) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga ® (regorafenib) and Bristol … with cancers typically not responsive to I-O therapy,” said Fouad Namouni, M.D., head of development, oncology, Bristol-Myers Squibb. “We are looking forward to a strong collaboration to investigate nivolumab with regorafenib, with the …

Scott Z. Fields

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer | PR Newswire | 7/18/2019

… Myers Squibb Company (NYSE: BMY ) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga ® (regorafenib) and Bristol … hope to deliver an additional therapeutic benefit to patients,” said Scott Z. Fields , M.D., senior vice president and head of Oncology Development at Bayer’s Pharmaceuticals Division. “We continue to invest in innovative approaches to maximize …

Mark Chao

Forty Seven’s (FTSV) CEO Mark McCamish on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/14/2019

… Hannah Deresiewicz – Stern Investor Relations Mark McCamish – Chief Executive Officer Chris Takimoto – Chief Medical Officer Ann Rhoads – Chief Financial Officer Mark Chao – Founder and Vice President of Clinical Development Conference Call Participants Matthew Harrison – Morgan … recent month, we were excited to enter into two new clinical collaboration, one with Genentech and one was Acerta, which allows us to evaluate 5F9 and Rituximab, as part of the triplet regimen, each with …

Michael Schmidt

Forty Seven’s (FTSV) CEO Mark McCamish on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/14/2019

… Mark Chao – Founder and Vice President of Clinical Development Conference Call Participants Matthew Harrison – Morgan Stanley Martin Auster – Credit Suisse Michael Schmidt – Guggenheim Arlinda Lee – Canaccord Mark Breidenbach – Oppenheimer Robert Hazlett – BTIG Operator Good day … recent month, we were excited to enter into two new clinical collaboration, one with Genentech and one was Acerta, which allows us to evaluate 5F9 and Rituximab, as part of the triplet regimen, each with …

Robert Forrester

Verastem Inc (VSTM) Q1 2019 Earnings Call Transcript - Nasdaq.com | 5/13/2019

… afternoon to discuss Verastem Oncology’s financial results and corporate highlights for the first quarter of 2019. I’m joined today by Robert Forrester, our President and Chief Executive Officer; Joe Lobacki, our Chief Commercial Officer; Dan … inhibitor defactinib, which is currently being evaluated in four separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types including pancreatic, non-small cell lung, ovarian and mesothelioma and …

Robert Forrest

Verastem Inc (VSTM) Q1 2019 Earnings Call Transcript - Nasdaq.com | 5/13/2019

… afternoon to discuss Verastem Oncology’s financial results and corporate highlights for the first quarter of 2019. I’m joined today by Robert Forrester, our President and Chief Executive Officer; Joe Lobacki, our Chief Commercial Officer; Dan … inhibitor defactinib, which is currently being evaluated in four separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types including pancreatic, non-small cell lung, ovarian and mesothelioma and …

Joseph Lobacki

Verastem, Inc. (VSTM) CEO Robert Forrester on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/10/2019

… Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants John Doyle - VP, IR Robert Forrester - President, CEO & Director Joseph Lobacki - EVP & Chief Commercial Officer Daniel Paterson - COO Robert Gagnon - CFO Conference Call Participants … inhibitor, defactinib, which is currently being evaluated in 4 separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, non-small cell lung, ovarian and mesothelioma. And …

Mike Morris

Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/2/2019

… Conference Call May 1, 2019 5:00 PM ET Company Participants Susan Hubbard – Executive Vice President-Public Affairs and Investor Relations Mike Morrissey – President and Chief Executive Officer Chris Senner – Chief Financial Officer P.J. Haley – Senior … our combination trials of cabozantinib with immune checkpoint inhibitor. Our clinical collaboration with BMS combining cabozantinib with nivolumab alone for cabozantinib with nivolumab and ipilimumab is making great progress. The ongoing Phase III CheckMate 9ER …

Leena Gandhi

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy | Business Wire | 11/29/2017

… associated with response to immunotherapy and key mechanisms through which the gut microbiota modulate immunotherapeutic responses. “Data from our ongoing clinical collaborations in melanoma show that gut bacteria signatures could help determine if a cancer … lung cancer, led, respectively, by Arjun V. Balar, M.D., and Leena Gandhi, M.D., Ph.D. Vedanta Biosciences’ immuno-oncology programs include lead product candidate, VE800, which has been shown in preclinical models to activate CD8+ T …

Gary G. Terrinoni

The Brooklyn Hospital Center and Mount Sinai Heart Collaborate to Provide Comprehensive Cardiac Care in Downtown Brooklyn | PR Newswire | 11/20/2017

clinical collaboration that provides access to comprehensive cardiac care in Downtown Brooklyn . The alliance makes it possible for TBHC to offer sophisticated preventive, diagnostic, interventional and treatment services such as electrophysiology (EP) studies and percutaneous coronary interventions (PCI). At The Brooklyn Hospital Center-Mount Sinai Heart comprehensive cardiac care celebration: Gary G. Terrinoni, TBHC President and CEO; Arthur Klein, MD, President, The Mount Sinai Health Network; Bernard Drayton, TBHC Trustee …

Samin Sharma

The Brooklyn Hospital Center and Mount Sinai Heart Collaborate to Provide Comprehensive Cardiac Care in Downtown Brooklyn | PR Newswire | 11/20/2017

… PRNewswire/ – The Brooklyn Hospital Center (TBHC) and Mount Sinai Heart hosted a breakfast reception on November 16 , to celebrate a clinical collaboration that provides access to comprehensive cardiac care in Downtown Brooklyn . The alliance makes … of transport out of the borough for such services,” said Samin Sharma, MD , Director of Clinical and Interventional Cardiology at The Mount Sinai Hospital. “ Mount Sinai has a 19-year track record of offering the …

Cleveland, Ohio

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients | 5/30/2020

clinical collaboration to assess the combination of SurVaxM (MimiVax) and pembrolizumab (Keytruda; MERCK). SurVaxM is a patented peptide immunogen targeting survivin, a cell-survival protein present in glioblastoma and many other cancers. (PRNewsfoto/MimiVax, LLC) This is a Phase 2 study now open at the Cleveland Clinic, Cleveland OH . The goal is to establish safety and tolerability of the drug combination and assess clinical activity of SurVaxM with pembrolizumab in …

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients | Benzinga | 5/30/2020

BUFFALO, N.Y. , May 30, 2020 /PRNewswire/ – MimiVax LLC, a clinical-stage biotechnology company in Buffalo, N.Y. , USA, developing immunotherapeutics for cancer and autoimmune diseases, announced a clinical collaboration to assess the combination of SurVaxM (MimiVax) and pembrolizumab (Keytruda; MERCK). SurVaxM is a patented peptide immunogen targeting survivin, a cell-survival protein present in glioblastoma and many other cancers. This is a Phase 2 study now open at the Cleveland Clinic …

Buffalo, New York

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients | 5/30/2020

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients News provided by May 30, 2020, 08:00 ET Share this article BUFFALO, N.Y. , May 30, 2020 /PRNewswire/ – MimiVax LLC, a clinical-stage biotechnology company in Buffalo, N.Y. , USA, developing immunotherapeutics for cancer and autoimmune diseases, announced a clinical collaboration to assess the combination of SurVaxM (MimiVax) and pembrolizumab (Keytruda; MERCK). SurVaxM is a patented peptide …

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients | Benzinga | 5/30/2020

BUFFALO, N.Y. , May 30, 2020 /PRNewswire/ – MimiVax LLC, a clinical-stage biotechnology company in Buffalo, N.Y. , USA, developing immunotherapeutics for cancer and autoimmune diseases, announced a clinical collaboration to assess the combination of SurVaxM (MimiVax) and pembrolizumab (Keytruda; MERCK). SurVaxM is a patented peptide immunogen targeting survivin, a cell-survival protein present in glioblastoma and many other cancers. This is a Phase 2 study now open at the Cleveland Clinic …